Home  |  Contact

UniProtKB/Swiss-Prot P00740: Variant p.Arg384Leu

Coagulation factor IX
Gene: F9
Variant information

Variant position:  384
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Arginine (R) to Leucine (L) at position 384 (R384L, p.Arg384Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and hydrophobic (L)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Thrombophilia, X-linked, due to factor IX defect (THPH8) [MIM:300807]: A hemostatic disorder characterized by a tendency to thrombosis. {ECO:0000269|PubMed:19846852}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In THPH8; factor IX Padua; higher specific activity than wild-type.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  384
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  461
The length of the canonical sequence.

Location on the sequence:   RSALVLQYLRVPLVDRATCL  R STKFTIYNNMFCAGFHEGGR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         RSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGR

                              RSASILQYLKVPLVDRATCLRSTKFTIYNNMFCAGFHEGGK

Chimpanzee                    RSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGR

Mouse                         RQASILQYLRVPLVDRATCLRSTTFTIYNNMFCAGYREGGK

Rat                           RQASILQYLRVPLVDRATCLRSTKFSIYNNMFCAGYREGGK

Bovine                        RSASILQYLKVPLVDRATCLRSTKFSIYSHMFCAGYHEGGK

Cat                           RPATILQYLKVPLVDRATCLRSTKFTIYNNMFCAGFHEGGK

Chicken                       RSAIVLQVLTVPFVDRVTCLKSTSTTILHSMFCAGYTAGGK

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 47 – 461 Coagulation factor IX
Chain 227 – 461 Coagulation factor IXa heavy chain
Domain 227 – 459 Peptidase S1
Disulfide bond 382 – 396
Mutagenesis 391 – 391 Y -> T. Strongly increases enzyme activity with a synthetic peptide substrate; when associated with F-305; T-311 and A-365.
Helix 379 – 384


Literature citations

X-linked thrombophilia with a mutant factor IX (factor IX Padua).
Simioni P.; Tormene D.; Tognin G.; Gavasso S.; Bulato C.; Iacobelli N.P.; Finn J.D.; Spiezia L.; Radu C.; Arruda V.R.;
N. Engl. J. Med. 361:1671-1675(2009)
Cited for: VARIANT THPH8 LEU-384; CHARACTERIZATION OF VARIANT THPH8 LEU-384; FUNCTION; SUBCELLULAR LOCATION; TISSUE SPECIFICITY;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.